VAXX · Vaxxinity, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $50.0K | - | $17.0K | - | $117.0K |
| Cost of Revenue | - | - | - | - | - | - | $1.93M | $1.0K | - | $9.0K |
| Gross Profit | - | - | - | - | - | - | ($1.93M) | $16.0K | - | $295.0K |
| R&D | - | $7.91M | $8.35M | $11.42M | - | $12.47M | $19.02M | $11.69M | - | $7.87M |
| SG&A | - | $5.54M | $6.08M | $7.38M | - | $7.30M | $5.85M | $8.58M | - | $5.12M |
| Total Operating Expenses | - | $13.45M | $14.43M | $18.81M | - | $19.77M | $24.87M | $20.27M | - | $30.32M |
| D&A | - | - | - | $586.0K | - | - | - | $282.00M | - | $400.0K |
| Operating Income | - | ($13.45M) | ($14.43M) | ($18.81M) | - | ($19.77M) | ($26.79M) | ($18.16M) | - | ($30.27M) |
| Interest Expense | - | $176.0K | $146.0K | $192.0K | - | $54.0K | $109.0K | $511.0K | - | $331.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | $0 |
| Net Income | - | ($13.14M) | ($13.98M) | ($18.42M) | - | ($19.25M) | ($17.25M) | ($32.02M) | - | ($30.39M) |
| EPS - Basic | - | ($0.10) | ($0.14) | ($0.15) | - | - | - | - | - | - |
| EPS - Diluted | - | ($0.10) | ($0.11) | ($0.15) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.93M | $17.39M | $37.06M | $22.59M | $33.48M | $18.88M | $109.07M | $124.77M | $144.88M | $89.38M |
| Accounts Receivable | - | - | - | - | - | - | - | - | $0 | $26.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | $2.97M | $1.89M | $3.03M | $5.29M | $3.32M | $338.0K | $1.46M | $3.19M | $3.90M |
| Current Assets | $33.23M | $46.36M | $59.70M | $73.43M | $93.89M | $108.08M | $122.02M | $133.35M | $154.13M | $35.67M |
| Total Assets | $44.31M | $57.48M | $71.37M | $85.53M | $106.40M | $122.96M | $137.00M | $147.53M | $166.67M | $134.92M |
| Current Liabilities | $17.61M | $21.56M | $23.78M | $26.47M | $30.94M | $32.43M | $29.29M | $24.41M | $27.49M | $30.68M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $30.90M | $33.77M | $36.35M | $39.40M | $44.22M | $42.70M | $39.66M | $34.87M | $38.05M | $41.29M |
| Stockholders' Equity | $13.41M | $23.70M | $35.01M | $46.13M | $62.18M | $80.26M | $97.34M | $112.66M | $128.62M | ($157.37M) |
| Retained Earnings | ($361.64M) | ($350.25M) | ($337.10M) | ($323.12M) | ($304.70M) | ($284.25M) | ($265.00M) | ($247.74M) | ($229.48M) | ($92.31M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($20.05M) | - | - | - | ($19.51M) | - | - |
| Investing Cash Flow | - | - | - | $8.74M | - | - | - | ($713.0K) | - | - |
| Financing Cash Flow | - | - | - | ($574.0K) | - | - | - | $46.28M | - | - |
| CapEx | - | - | - | $172.0K | - | - | - | $713.0K | - | - |
| Free Cash Flow | - | - | - | ($20.22M) | - | - | - | ($20.23M) | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | 94.1% | - | 252.1% |
| Operating margin | - | - | - | - | - | -39536.0% | - | -106847.1% | - | -25876.1% |
| EBITDA margin | - | - | - | - | - | - | - | 1551976.5% | - | -25534.2% |
| Net margin | - | - | - | - | - | -38504.0% | - | -188358.8% | - | -25973.5% |
| Free cash flow margin | - | - | - | - | - | - | - | -118982.4% | - | - |
| FCF / Net income | - | - | - | 1.10 | - | - | - | 0.63 | - | - |
| R&D / Revenue | - | - | - | - | - | 24936.0% | - | 68752.9% | - | 6723.9% |
| SG&A / Revenue | - | - | - | - | - | 14600.0% | - | 50494.1% | - | 4377.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -22.9% | -19.6% | -21.5% | - | -15.7% | -12.6% | -21.7% | - | -22.5% |
| Return on equity | - | -55.5% | -39.9% | -39.9% | - | -24.0% | -17.7% | -28.4% | - | 19.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.89 | 2.15 | 2.51 | 2.77 | 3.03 | 3.33 | 4.17 | 5.46 | 5.61 | 1.16 |
| Quick ratio | 1.89 | 2.15 | 2.51 | 2.77 | 3.03 | 3.33 | 4.17 | 5.46 | 5.61 | 1.16 |
| Cash ratio | 0.28 | 0.81 | 1.56 | 0.85 | 1.08 | 0.58 | 3.72 | 5.11 | 5.27 | 2.91 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -76.4x | -98.8x | -98.0x | - | -366.1x | -245.8x | -35.5x | - | -91.5x |
| Equity multiplier | 3.30 | 2.42 | 2.04 | 1.85 | 1.71 | 1.53 | 1.41 | 1.31 | 1.30 | -0.86 |
| Liabilities / Assets | 0.70 | 0.59 | 0.51 | 0.46 | 0.42 | 0.35 | 0.29 | 0.24 | 0.23 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | 0.00 | - | 0.00 | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | 81d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | 64d | 532900d | - | 158369d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | 7.3x | 9.1x | 6.2x | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | -57.3% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 32.0% | 46.2% | -3.5% | - | 34.7% | - | - | - | - |
| Net income growth (YoY) | - | 31.7% | 19.0% | 42.5% | - | 36.6% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 0.0% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -78.4% | -70.5% | -64.0% | -59.0% | -51.7% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vaxxinity against the 5 most active filers in the same SIC group.